|
PT2334295T
(pt)
|
2008-09-02 |
2017-09-15 |
Amarin Pharmaceuticals Ie Ltd |
Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
|
|
KR20110091680A
(ko)
|
2008-10-17 |
2011-08-12 |
메타볼렉스, 인코포레이티드 |
작고 조밀한 ｌｄｌ 입자를 감소시키는 방법
|
|
CN107233337A
(zh)
|
2009-04-29 |
2017-10-10 |
阿马里纳药物爱尔兰有限公司 |
含有epa和心血管剂的药物组合物以及使用其的方法
|
|
SI2424356T1
(en)
|
2009-04-29 |
2018-01-31 |
Armarin Pharmaceuticals Ireland Limited |
A stable pharmaceutical composition and procedures for its use
|
|
WO2010147994A1
(en)
|
2009-06-15 |
2010-12-23 |
Amarin Pharma, Inc. |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
MX2012003555A
(es)
|
2009-09-23 |
2012-07-03 |
Amarin Corp Plc |
Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
|
|
US9719068B2
(en)
|
2010-05-06 |
2017-08-01 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
NZ727980A
(en)
|
2010-11-29 |
2018-08-31 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
EP2775837A4
(en)
|
2011-11-07 |
2015-10-28 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF TREATING HYPERTRIGLYCERIDEMIA
|
|
ES2891473T3
(es)
|
2012-01-06 |
2022-01-28 |
Amarin Pharmaceuticals Ie Ltd |
Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
|
|
EP3815684B1
(en)
|
2012-06-29 |
2024-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
|
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US9814733B2
(en)
*
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
US10272058B2
(en)
|
2014-03-20 |
2019-04-30 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
DK3119384T3
(en)
|
2014-03-20 |
2018-12-03 |
Cymabay Therapeutics Inc |
TREATMENT OF INTRAHEPATHIC COLESTASTIC DISEASES
|
|
UA121208C2
(uk)
|
2014-04-11 |
2020-04-27 |
Сімабей Терапьютікс, Інк. |
Лікування нажхп та насг
|
|
SG10201801654RA
(en)
|
2014-05-28 |
2018-04-27 |
Childrens Hospital Med Ct |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
AU2015331848B2
(en)
|
2014-10-17 |
2022-03-03 |
Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center |
In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
|
|
US20180117013A1
(en)
*
|
2015-03-26 |
2018-05-03 |
T3D Therapeutics, Inc. |
Methods of treating liver disease using indane acetic acid derivatives
|
|
CN107530306A
(zh)
|
2015-04-28 |
2018-01-02 |
普罗诺瓦生物医药挪威公司 |
结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
|
|
US10940125B2
(en)
|
2015-09-18 |
2021-03-09 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
WO2017139708A1
(en)
|
2016-02-10 |
2017-08-17 |
Synlogic, Inc. |
Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
US12053445B2
(en)
|
2016-03-31 |
2024-08-06 |
Genfit |
Methods of treatment of cholestatic diseases
|
|
CN109415685B
(zh)
|
2016-05-05 |
2023-07-04 |
儿童医院医疗中心 |
用于体外制造胃底组织的方法和与其相关的组合物
|
|
GB201614455D0
(en)
*
|
2016-08-24 |
2016-10-05 |
Univ Oxford Innovation Ltd |
Biomarkers
|
|
EP3534976A4
(en)
*
|
2016-11-04 |
2020-09-16 |
Children's Hospital Medical Center |
PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE
|
|
US10493363B2
(en)
*
|
2016-11-09 |
2019-12-03 |
Activision Publishing, Inc. |
Reality-based video game elements
|
|
CA3045145A1
(en)
|
2016-12-05 |
2018-06-14 |
Children's Hospital Medical Center |
Colonic organoids and methods of making and using same
|
|
WO2018191673A1
(en)
|
2017-04-14 |
2018-10-18 |
Children's Hospital Medical Center |
Multi donor stem cell compositions and methods of making same
|
|
EP3619193B1
(en)
|
2017-05-05 |
2023-03-22 |
Hepanova, Inc. |
Amino-aryl-benzamide compounds and methods of use thereof
|
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US10512622B2
(en)
|
2017-07-14 |
2019-12-24 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
US20200276178A1
(en)
|
2017-09-13 |
2020-09-03 |
Novartis Ag |
Combinations comprising fxr agonists
|
|
JP2020536529A
(ja)
|
2017-10-10 |
2020-12-17 |
チルドレンズ ホスピタル メディカル センター |
食道組織および／または臓器組成物およびそれを作製する方法
|
|
US11260066B2
(en)
|
2017-10-27 |
2022-03-01 |
Samyang Corporation |
Inhibiting reduction of lean body mass and inhibiting accumulation of liver fat by administering allulose
|
|
ES2996688T3
(en)
|
2017-12-06 |
2025-02-13 |
Basf As |
Fatty acid derivatives for treating non-alcoholic steatohepatitis
|
|
WO2019126626A1
(en)
|
2017-12-21 |
2019-06-27 |
Children's Hospital Medical Center |
Digitalized human organoids and methods of using same
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
EP3826652B1
(en)
|
2018-07-26 |
2026-02-25 |
Children's Hospital Medical Center |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
EP3849568A4
(en)
|
2018-09-12 |
2022-06-15 |
Children's Hospital Medical Center |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
ES2983568T3
(es)
|
2018-09-24 |
2024-10-23 |
Amarin Pharmaceuticals Ie Ltd |
Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto
|
|
EP3880187A1
(en)
*
|
2018-11-16 |
2021-09-22 |
CymaBay Therapeutics, Inc. |
Treatment of obesity and its complications
|
|
KR20210092754A
(ko)
*
|
2018-11-16 |
2021-07-26 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
Nafld 및 nash의 병용 치료
|
|
CN121081472A
(zh)
|
2018-12-13 |
2025-12-09 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
EP3976066A4
(en)
|
2019-05-31 |
2023-06-28 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
AU2020283048A1
(en)
|
2019-05-31 |
2021-12-23 |
Children's Hospital Medical Center |
Shaped organoid compositions and methods of making same
|
|
EP4017875A4
(en)
|
2019-08-23 |
2023-05-03 |
Terns Pharmaceuticals, Inc. |
THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
|
|
AU2020346057A1
(en)
|
2019-09-12 |
2022-04-21 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
EP4058141A4
(en)
|
2019-11-12 |
2023-11-22 |
Amarin Pharmaceuticals Ireland Limited |
METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter
|
|
WO2021097027A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Seladelpar for use in the treatment of alcoholic liver disease
|
|
WO2021097034A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
|
|
AU2021273487A1
(en)
*
|
2020-05-13 |
2023-01-05 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
AU2022263358A1
(en)
|
2021-04-21 |
2023-11-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|
|
US20240216312A1
(en)
*
|
2021-05-11 |
2024-07-04 |
Genfit |
Ppar-agonists for use in the treatment of liver failure
|